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Copyright © 2010 JCBN Summary Preeclampsia (PE) is a major contributor to maternal and fetal mortality. The
cause of preeclampsia remains unclear, but oxidative stress on the endothelium leading to
endothelial dysfunction is said to be the root cause of the disease. The aim of this study was
to measure and determine the plasma levels of key angiogenic factors in pregnancy as an
indicator for the early onset of preeclampsia in pregnancy. Plasma levels of circulating a
soluble fms like tyrosine kinase-1 (sFlt-1), an anti-angiogenic factor, vascular endothelial
growth factor (VEGF) and placental growth factor (PIGF), both pro-angiogenic factors were
analyzed in normal pregnant Malaysian women (control group, n = 34), women with pregnant
induced hypertension (PIH, n = 34) and women with preeclampsia (PE, n = 34) all at three
gestational ages, 24–28 weeks (early pregnancy: EP), 32–36 weeks (late pregnancy: LP) and
6 weeks after delivery (postpartum: PN). The plasma levels of angiogenic factors were
determined by ELISA. sFlt-1 levels were elevated in PIH and PE patients as compared to
controls. PIGF and VEGF were significantly decreased in PIH and PE as compared to the
controls. These results suggest that elevated concentration of sFlt-1 and suppressed levels of
PIGF and VEGF may contribute to the development of hypertension in pregnancy which
precedes preeclampsia.
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Introduction
Preeclampsia (PE) is a hypertensive disorder in pregnancy
associated with high blood pressure and proteinuria which
frequently develops after 20 weeks of gestation [1]. This
disorder affects between 2–7% of pregnancies worldwide
and it’s the major cause of maternal and fetal mortality
[2, 3]. The etiology of this disease remains unclear, however
the pathophysiological changes seen in preeclampsia include
increased vasoconstriction and coagulation, vascular endo-
thelial dysfunction and reduced placental perfusion [4].
Until recently, most investigations on PE were focused on
reduced placental perfusion [5]. During placental perfusion
cytotrophoblast invasion does not occur due to improper dif-
ferentiation of maternal uterine spiral arteries. This reduces
the blood flow in the placenta which subsequently causes
poor oxygen and nutrient transfer between mother and fetus
[6]. Consequently, this leads to endothelial dysfunction
which is the primary cause of PE [7]. However, in the last
few years, there has been increased focus on the role of an-
giogenic factors in PE.
Recent studies suggested that there are imbalances in
the production level of circulating pro- and anti-angiogenic
factors and have implicated this in endothelial dysfunction
[8]. The concentration of the anti-angiogenic factor, soluble
fms like tyrosine kinase-1 (sFlt-1) was found to be increased
in the plasma of preeclamptic women [8–10]. sFlt-1 antago-S. Yelumalai et al.
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nizes the action of the pro-angiogenic factors, vascular en-
dothelial growth factor (VEGF) and ploncental growth
factor (PIGF) [11–14] by adhering to the receptor binding
domains of VEGF and PIGF. This prevents their interaction
with endothelial cell surface receptors and subsequently re-
sults in endothelial dysfunction leading to preeclampsia
[15]. Levels of circulating VEGF and PIGF were found to be
significantly lowered in preeclamptic women compared to
controls [8, 16, 17].
The objective of this study was to compare the plasma
levels of angiogenic factors in normal pregnant women,
pregnant women with induced hypertension and pre-
eclamptic patients at three different gestational ages. We
also investigated the potential for these angiogenic factors to
serve as a biomarker for early detection of PE.
Materials and Methods
Study Population
The subjects were recruited from the Obstetric Unit of the
University of Malaya Medical Centre (UMMC) with the
study protocol approved by the UMMC Ethics Committee.
Thirty four subjects from each of the three categories: (i)
pregnancy induced hypertension (PIH), (ii) preeclampsia
and (iii) controls (normal pregnant women) were enrolled in
this study. Single and multiparous women participated in
this study. Blood samples were collected at three gestational
ages: (i) early pregnancy (EP) (24–28 weeks), (ii) late
pregnancy (LP) (32–36 weeks) and (iii) postpartum (PN)
(6 weeks after delivery). Subjects classified as preeclamptic
met one or more of the following diagnostic criteria: systolic
blood pressure ≥140 mmHg or a diastolic pressure of
≥90 mmHg taken on two occasions at least six hours apart
and proteinuria of ≥0.3 gm/dl in a 24 h urine collection or
2+ based on semiquantitative urine analysis. Patients with
PIH (gestational hypertension) met the following criteria:
systolic pressure of ≥140 mmHg and a diastolic pressure of
≥90 mmHg without proteinuria after 20 weeks of gestation
with resolution to baseline by 12 weeks postpartum. Normal
pregnant women met the following criteria: pregnancy
with normal blood pressure (<140/90 mmHg), absence of
proteinuria, without medical and obstetrical complications.
Exclusion criteria for all subjects were heart disease, use
of antihypertensive medication, diabetes mellitus and renal
disease. All subjects were asked to give informed consent to
be included in the study after the nature of the research had
been explained to them.
Sample preparation
Venous blood sample (10 ml) was collected from each
subject. Blood was dispensed into 3.0 ml EDTA (1 mg/ml)
containing vacutainer tubes and centrifuged at 7,000 r.p.m
for 15 min. Plasma obtained was aliquoted under sterile
conditions and stored at −80°C. Approximately 1.5 ml of
sample was used to determine the renal profile.
Measurement of sFlt-1, VEGF and PIGF
Plasma concentration sFlt-1, VEGF and PIGF were
measured in duplicate using commercially available ELISA
kits from R&D System Inc. (Minneapolis). Plasma samples
for sFlt-1 measurement were diluted to 20 fold with the
calibrator diluent provided. 100 μl of diluent was added into
each well of the 96 well plates precoated with antibodies
against sFlt-1 or VEGF or PIGF. This was followed by the
addition of 100 μl of each standard or diluted plasma
samples into their respective wells. The plate was then
incubated for 2 h on an orbital shaker. Washing was per-
formed four times using wash buffer to remove any unbound
compounds followed by incubation for 2 h with 200 μl
polyclonal antibody. Another 4 cycles of washing with the
wash buffer was performed. 200 μl of substrate solution
were added to each well and plate was incubated in the
dark for 30 min. 50 μl of stop solution was added to each
well to stop further reaction.
The optical density was measured at 450 nm and 540 nm.
The plasma levels of each factor were calculated using
standard curves derived from a known concentration of the
respective recombinant factors.
Statistical analysis
Experimental data obtained in triplicates were expressed
as mean ± SD. Statistical analysis was performed by using the
non-parametric Kruskal-Wallis one-way ANOVA followed
by Dunn’s test. A p value of less than 0.0001 was considered
to show significant differences between the groups. Statistical
calculations were carried out using the software Graphpad
Prism, version 5.0 (Graph Pad Software Inc., Los Angeles).
Results
Clinical features of the subjects as wells as the basic
demographic characteristics are tabulated (Table 1). There
were no significant differences observed in maternal age
between the three groups. Systolic and diastolic levels were
found significantly increased in women with pregnancy
induced hypertension and preeclampsia as compared to
normal pregnant women.
Plasma concentrations of sFlt-1, PIGF and VEGF are
shown in Fig. 1. In general, the concentration of sFlt-1 was
found to be in the order of PE > PIH > Control. In contrast,
the concentrations of pro-angiogenic factors, PIGF Fig. 1 (b)
and VEGF Fig. 1 (c), were significantly lowered when
compared to the control group.
Within the PE group, sFlt-1 values during LP
(10058.79 ± 2678.684 pg/ml) is significantly higher as com-
pared to EP (7220.141 ± 2148.333 pg/ml) and significantlyAngiogenic Factors in Preeclampsia
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lower compared to PN (5294.725 ± 1161.516 pg/ml). This
pattern is similar for PIH and Controls. There were no
significant differences on sFlt-1 concentration in PE, PIH
and controls after delivery.
Fig. 1 (b) and (c) shows the concentration of PIGF and
VEGF respectively in the three groups at three gestational
ages. The levels of the pro-angiogenic factors (PIGF and
VEGF) were inversely related to sFlt-1 levels in PE, PIH
and Controls. Postpartum VEGF values were found to be
approximately equivalent between PE, PIH and Controls.
Imbalance in the levels of pro- and anti-angiogenic factors
in the three groups at three gestational ages is summarized
in Fig. 2 (a–c). In the control group (Fig. 2a), it is evident
that PIGF levels are persistantly higher than sFlt-1 levels.
However, in the PIH and PE groups, higher sFl-1 persisted
throughout pregnancy. We also analyzed the ratio of log
[sFlt-1/PIGF] in the maternal plasma of the preeclampsia
patients and controls. The plasma log [sFlt-1/PIGF] ratio
was significantly higher in the preeclampsia subjects than
in controls (Fig. 3).
Discussion
Preeclampsia is a systemic syndrome featuring the
development of hypertension and proteinuria at the second
trimester of pregnancy that causes significant medical com-
plications for both mother and fetus [18,  19]. Previous
studies have show that the levels of circulating sFlt-1 and
other anti-angiogenic factors including endoglin are found to
be elevated in preeclamptic women compared to normal
pregnant women [8, 15, 20–22].
Inhibition of pro-angiogenic factors by increased levels of
sFlt-1 leads to endothelial dysfunction. Endothelial function
can be restored in vitro by exogenous PIGF and VEGF [23].
During pregnancy, circulating sFlt-1 was found to be higher
in preeclamptic subjects when compared to levels in non–
pregnant women [24].
Our investigation demonstrated a marked imbalance
between circulating plasma levels of soluble fms like
tyrosine kinase-1, (sFlt-1) and pro-angiogenic factors (PIGF
and VEGF) in both pregnancy induced hypertension (PIH)
and preeclamptic (PE) women compared to normal pregnant
women (Fig. 2a, b and c) at all stages of pregnancy.
The role of VEGF in preeclamptic women has drawn
huge attention. There have been some studies reporting
decreased levels or even elevated levels of VEGF in PE
[25–28]. We, however, observed significantly lower levels
of VEGF in our study in PE subjects (Fig. 1c). Furthermore,
lower levels of PIGF were observed in preeclamptic subjects
(Fig. 1b). Our investigations suggest that elevated levels
Table 1. Clinical features of subjects
*Significant as compared to control (p<0.001).
Characteristic Controls PIH PE
Age 29.6 ± 7.9 33.4 ± 5.5 29.7 ± 4.8
Races
Malay 30 (88.2%) 31 (91.2%) 17 (50.0%)
Chinese 2 (5.9%) 3 (8.8%) 11 (32.4%)
Indian 2 (5.9%) 0 6 (0.18%)
Early Pregnancy (EP) 
24–28 weeks
Systolic blood pressure (mmHg) 106 ± 5.9 132 ± 6.8* 156 ± 8.4*
Diastolic blood pressure (mmHg) 70 ± 2.54 85 ± 4.52* 98 ± 4.57*
Plasma Urea (mmol/L) 2.38 ± 0.5 2.26 ± 0.62* 3.0 ± 1.5*
Plasma Creatinine (µmol/L) 41.6 ± 8.0 41.6 ± 9.2 49.8 ± 10.1*
Late Pregnancy (LP) 
32–36 weeks
Systolic blood pressure (mmHg) 115 ± 5.6 135 ± 5.2* 164 ± 6.2*
Diastolic blood pressure (mmHg) 78 ± 2.98 90 ± 5.4* 95 ± 6.35*
Plasma Urea (mmol/L) 2.06 ± 0.39 3.2 ± 0.73* 4.3 ± 2.2*
Plasma Creatinine (µmol/L) 50.5 ± 10.6 47.6 ± 13.1* 60.9 ± 12.5*
Postpartum (6 weeks after delivery)
Systolic blood pressure (mmHg) 113 ± 5.87 122 ± 6.45* 131 ± 6.89*
Diastolic blood pressure (mmHg) 80 ± 4.52 76 ± 3.98* 91 ± 4.98*
Plasma Urea (mmol/L) 4.15 ± 1.2 3.5 ± 1.1* 4.2 ± 1.4*
Plasma Creatinine (µmol/L) 59.4 ± 14.02 59.4 ± 11.4 57.6 ± 11.4*S. Yelumalai et al.
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of sFlt-1 precede the endothelial dysfunction seen in
preeclampsia, since imbalances in pro and anti-angiogenic
factors occur in the early stages of pregnancy in subjects
who are preeclamptic.
Maynard and coworkers [8] showed an increased level of
sFlt-1 followed by decreased levels of pro-angiogenic factor
in maternal serum of preeclamptic women compared to
controls. Similarly, Park and group [29] reported that
levels of maternal serum sFlt-1 were higher in preeclampsia
compared to controls. They indicated that the sFlt-1 levels
in severe preeclampsia were elevated compared to mild
preeclampsia and an elevated maternal sFlt-1 level is a risk
factor in developing preeclampsia.
Several factors in our study clearly suggest that increased
placental production of sFlt-1 may contribute to the patho-
genesis of preeclampsia. Plasma levels of sFlt-1 were found
to be elevated in preeclampsia, although it was not
significantly increased in the PIH patients. This suggests
that, sFlt-1 plays a major role in preeclampsia but not in
pregnancy induced hypertension.
Inappropriate modification of maternal uterine spiral
arteries [30] results in increased production of sFlt-1. This
prevents cytotrophoblast cell invasion which leads to
placental perfusion and subsequently develops into hypoxia
[7]. The angiogenic proteins, sFlt-1, VEGF, PIGF seems to
act as an essential regulatory factor in early development
of placenta and pseudovasculogenesis [8]. Zhou and group
suggested that exogenous sFlt-1 inhibits placental cyto-
trophoblast invasion in vitro [23]. Overproduction of sFlt-1
damages the endothelium in 28 – 36 weeks of gestational
ages. Furthermore elevated sFlt-1 levels may be considered
as the root cause in improper placental differentiation in
preeclampsia [8].
Our results have important implications both thera-
peutically and diagnostically for the usage of pro-angiogenic
proteins in preeclampsia and pregnancy induced hyper-
tension as well as in other diseases such as cancer [8]. Our
study shows that the over expression of sFlt-1 and signifi-
cantly lower levels of proangiogenic factors in early
pregnancy can be used as a biomarker for the onset of preec-
lampsia and PIH disease. Therapies and preventive strategies
for preeclampsia must target the imbalance of these factors.
Differences in the production of circulating angiogenic
factors, weeks prior to the onset of preeclampsia are
Fig. 1. Graph shows sFlt-1(a), PIGF (b), VEGF (c) concentrations in maternal plasma of control, hypertension (PIH) and preeclampsia
(PE), at three different gestational ages [mid Pregnancy (EP), late pregnancy (LP) and Postpartum (PN)]. Top and bottom
horizontal edges denote the 75th and 25th percentiles respectively. The middle line inside the box plots indicates median and the
vertical whiskers above and below the boxes shows the largest and smallest values. *, **p<0.05 as compared to control groups,
***p<0.001 as compared to control groups.Angiogenic Factors in Preeclampsia
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potential biomarkers for screening and/or diagnosis. Signifi-
cant increase in sFlt-1 and decrease in pro-angiogenic
factors may be noticed from 2nd trimester onwards [29, 31]
and is evident 5–8 weeks prior to onset of the disease [15, 22].
Maternal plasma sFlt-1 concentrations are specifically
elevated in severe preeclampsia and early onset preec-
lampsia [15, 32]. Serum levels of PIGF are decreased in
patients who develop preeclampsia as early as 12 weeks of
gestational age [33] although by 18–20 weeks of gestational
age the decrease is marked [15, 18, 19].
Previous reports have shown that the sFlt-1: PIGF ratio
can be used as an index of anti-angiogenic activity that
reflects alteration in both biomarkers [34]. It serves as a
better biomarker for identifying early onset of preeclampsia
than either one. [22]. PIGF levels of the controls were
positively correlated, while those of the preeclampsia
patients were negatively correlated with sFlt-1 levels. Our
study revealed that the sFlt-1/PIGF ratio in the PE patients
was significantly higher compared to control.
If increased level of sFlt-1 is a feature of preeclampsia,
inhibiting its action may be a strategy to prevent the onset
Fig. 2. Box plot represents angiogenic factors concentration in control (a), hypertension (PIH) (b) and preeclampsia (PE) (c), at three
different gestational ages, [mid pregnancy (EP, 24–28 weeks), late pregnancy (LP, 32–36 weeks) and postpartum (PN, 6 weeks
after delivery)]. *, **p<0.05 as compared to control groups, ***p<0.001 as compared to control groups.
Fig. 3. Correlation between sFlt-1 and PIGF levels in maternal
plasma of the PE (closed circle) and controls (open
circle) (p<0.001).S. Yelumalai et al.
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of this disease. Maynard et al. [ 8] who used an in vitro
angiogenesis assay, suggested that exogenous VEGF/PIGF
therapy might restore endothelial function in preeclamptic
patients. Therapy using pro-angiogenic molecules may be
relevant here. In this context, nicotine may be considered
since it has been shown to stimulate angiogenesis [35].
Furthermore, smoking individuals showed lower incidence
of PE [36] by lowering sFlt-1 levels in human [37]. Hence,
short term use of nicotine in cases of severe preeclampsia
might be an effective treatment.
Alteration in the role of the placenta and oxidative stress
level were seen in high risk preeclamptic women who
consumed antioxidant complement [38]. Oral administration
of supplementary antioxidants such as vitamin C and E has
shown to diminish the risk of preeclampsia in pregnant
women [39]. Report showed that the consumption of
vitamin C and E influences the enzymatic activity of anti-
oxidant and suppresses the development of preeclampsia [40].
Therefore, vitamin C and E can be used as a definite anti-
oxidant for treating and preventing the risk of preeclampsia.
Conclusion
Overall, our findings showed overproduction of sFlt-1
in pregnancies that could contribute to proteinuria and
abnormal blood pressure levels in preeclampsia and PIH
subjects. We also found significant reduction in the levels
of pro-angiogenic factors in these patients compared to
controls. Excessive levels of sFlt-1 presenting in early
pregnancy may be used as a biomarker for early detection
of preeclampsia or any pregnancy hypertensive disorder.
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